Literature DB >> 35731192

Determining Infected Aortic Aneurysm Treatment Using Focused Detection of Helicobacter cinaedi.

Jien Saito, Emiko Rimbara, Shingo Inaguma, Chihiro Hasegawa, Shinji Kamiya, Akihiro Mizuno, Yoshiaki Sone, Tatsuhito Ogawa, Yukihide Numata, Satoru Takahashi, Miki Asano.   

Abstract

We detected Helicobacter cinaedi in 4 of 10 patients with infected aortic aneurysms diagnosed using blood or tissue culture in Aichi, Japan, during September 2017-January 2021. Infected aortic aneurysms caused by H. cinaedi had a higher detection rate and better results after treatment than previously reported, without recurrent infection.

Entities:  

Keywords:  Helicobacter cinaedi; Japan; antimicrobial treatment; aortic aneurysm; arteriosclerosis; bacteria; infections

Mesh:

Year:  2022        PMID: 35731192      PMCID: PMC9239880          DOI: 10.3201/eid2807.212505

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   16.126


Infected aortic aneurysms account for 0.7%–3% of all aortic aneurysms and are associated with a 26%–44% mortality rate (). No consensus exists about appropriate antimicrobial therapy and treatment duration for infected aneurysms. Moreover, determining surgical treatment in each case requires carefully considering the causative bacterium and the patient’s medical background (). Recently, several cases of infected aortic aneurysms caused by Helicobacter cinaedi, a rare, difficult-to-detect causative bacterium have been reported (). First identified in 1984, H. cinaedi, a gram-negative rod with spiral morphology and bipolar flagella, is indigenous to the intestinal tract of humans and other animals (,). This bacterium produces a cytolethal distending toxin that invades epithelial cells () and is associated with bacteremia in compromised hosts and infected aortic aneurysms, mediated by bacterial translocation from the intestinal mucosa (,). Because of the high recurrence rate for H. cinaedi bacteremia, it is recommended that patients receive prolonged treatment of at least 3 months with appropriate antimicrobial drugs (). We sought to determine the efficacy of treatment for infected aortic aneurysms through the focused detection of H. cinaedi.

The Study

During September 2017–January 2021, we treated 10 patients with infected aortic aneurysms from a single center in Aichi, Japan. Diagnosis, including for recurrent aneurysms, was based on either positive culture or PCR of aortic tissue resected at the time of surgery or positive blood or puncture culture of an abscess caused by a hematogenous infection in patients who did not undergo open surgery and had clinical findings localized to the aortic aneurysm. We started patients on antimicrobial therapy with meropenem when H. cinaedi was suspected or gram-negative rods were identified, then changed to sulbactam/ampicillin after confirming drug sensitivity. After 4 weeks of treatment or a negative inflammatory reaction, the antimicrobial treatment was switched to minocycline or amoxicillin/clavulanate for 3–6 months. If other causative bacteria were identified, antimicrobial drugs were changed based on drug sensitivity results and continued for 3–6 months. Rifampin-soaked graft replacement was the first-choice surgical treatment, irrespective of causative bacterium. Among the 10 patients with infected aortic aneurysms, H. cinaedi was the causative bacterium in 4, Staphylococcus aureus in 3, Salmonella enterica serovar Enteritidis in 1, and Enterobacter cloacae in 1. Treatment included vascular replacement in 7 patients (2 with H. cinaedi), endovascular stent grafting in 1 (with H. cinaedi), and medical treatment in 2 patients (1 with H. cinaedi). One patient with aortic rupture and Salmonella Enteritidis infection died postoperatively from multiorgan failure; the other 9 patients had good courses of recovery without recurrence (Table 1).
Table 1

Demographic and clinical variables of 10 patients with infected aortic aneurysms with or without Helicobacter cinaedi, Aichi, Japan, September 2017–January 2021*

VariablesTotal, n = 10H. cinaedi, n = 4Non–H. cinaedi, n = 6
Age, median (IQR)
77 (70.5–83.0)
77.5 (70.0–84.3)
77 (71.0–82.3)
Sex
M835
F
2
1
1
Comorbidity
Diabetes mellitus321
Chronic kidney disease110
Cancer
2
1
1
Steroid use
1
0
1
Sign or symptom
Pain835
Fever734
Shock
1
0
1
Laboratory findings, median (IQR)
Leukocytes, × 103 cells/μL9.6 (8.8–11.0)8.4 (7.4–9.5)1.1 (9.5–17.2)
C-reactive protein, mg/dL7.6 (5.1–22.1)4.3 (3.8–5.1)21.6 (11.0–23.6)
Procalcitonin, ng/dL
0.19 (0.05–0.76)
0.14 (0.04–0.38)
0.38 (0.08–1.53)
Aneurysm diameter, mm, median (IQR)
40.5 (32.8–44.8)
32.5 (25.5–39.8)
44.5 (37.3–55.5)
Aneurysm location
Thoracic aorta110
Thoracoabdominal aorta101
Abdominal aorta
8
3
5
Aneurysm form
Saccular743
Fusiform
3
0
3
Rupture
3
0
3
Aortoduodenal fistula
2
0
2
Surgery
Emergency303
Urgent211
Elective532
Endovascular
1
1
0
Nonsurgical treatment only
2
1
1
Death101

*IQR, interquartile range.

*IQR, interquartile range. All 4 of the H. cinaedi–infected case-patients were immunocompromised (diabetes mellitus, chronic kidney disease, cancer). However, their clinical findings were mild, and C-reactive protein levels tended to be low (H. cinaedi/non–H. cinaedi median 4.3/21.6 mg/dL) at hospital admission. All patients had saccular aneurysms and severely calcified aortas. Surgical findings showed highly adherent areas around the aneurysms with intimal defects but without abscess formation. Pathological examination revealed severe lymphocytic infiltration in the aneurysmal wall with loss of elastic fibers. In contrast, 3 of 5 patients in the non–H. cinaedi group showed abscesses and hematomas around the infections (Figure 1).
Figure 1

Contrast-enhanced computed tomography imaging for Case-patient 3 in the Helicobacter cinaedi group of 10 patients with infected aortic aneurysms with or without H. cinaedi, Aichi, Japan, September 2017–January 2021. A, B) The infrarenal aortic aneurysm had a maximum short diameter of 39 mm and a cystic protrusion of 19 mm (arrow in panel A) before the operation. C) After the operation, the adipose tissue concentration increased around the aneurysm (arrow).

Contrast-enhanced computed tomography imaging for Case-patient 3 in the Helicobacter cinaedi group of 10 patients with infected aortic aneurysms with or without H. cinaedi, Aichi, Japan, September 2017–January 2021. A, B) The infrarenal aortic aneurysm had a maximum short diameter of 39 mm and a cystic protrusion of 19 mm (arrow in panel A) before the operation. C) After the operation, the adipose tissue concentration increased around the aneurysm (arrow). We performed blood cultures using the BacT/Alert system (bioMérieux, https://www.biomerieux.com) and grew microaerobic cultures in the presence of hydrogen using a commercial hydrogen generator (SUGIYAMA-GEN Co., Ltd., http://sugiyama-gen.com). In the H. cinaedi group, we used multilocus sequence typing (MLST) to identify the subtype, and we immunostained aortic tissues with antiserum against the whole-cell lysate of H. cinaedi raised in rabbits (Figure 2; Appendix Figure) ().
Figure 2

Comparison of images from patients in the Helicobacter cinaedi group with patients from the non–H. cinaedi group among 10 patients with infected aortic aneurysms with or without H. cinaedi, Aichi, Japan, September 2017–January 2021. Immunohistochemistry was performed on the whole cell lysates of H. cinaedi strain MRY08-1234 isolated from immunocompromised patients in Japan by raising anti–rabbit H. cinaedi IgG. One of 2 case-patients with resected tissue in the H. cinaedi group had positive immunostaining (patient 1). A–C) Case-patient 1 in the H. cinaedi group. D–F) Case-patient 4 in the non–H. cinaedi group. In images from both patients, lymphocyte and neutrophil infiltrates, cholesterol clefts, foam cells, plasma cells, foreign body giant cells, and hemosiderin deposition are visible (A, B, D, E; hematoxylin & eosin). Immunohistochemistry stain shows of H. cinaedi organisms in the aortic intima (arrow in C) and negative results (F). Scale bars: 1,000 µm in A, D; 100 µm in B, E; 50 µm in C, F.

Comparison of images from patients in the Helicobacter cinaedi group with patients from the non–H. cinaedi group among 10 patients with infected aortic aneurysms with or without H. cinaedi, Aichi, Japan, September 2017–January 2021. Immunohistochemistry was performed on the whole cell lysates of H. cinaedi strain MRY08-1234 isolated from immunocompromised patients in Japan by raising anti–rabbit H. cinaedi IgG. One of 2 case-patients with resected tissue in the H. cinaedi group had positive immunostaining (patient 1). A–C) Case-patient 1 in the H. cinaedi group. D–F) Case-patient 4 in the non–H. cinaedi group. In images from both patients, lymphocyte and neutrophil infiltrates, cholesterol clefts, foam cells, plasma cells, foreign body giant cells, and hemosiderin deposition are visible (A, B, D, E; hematoxylin & eosin). Immunohistochemistry stain shows of H. cinaedi organisms in the aortic intima (arrow in C) and negative results (F). Scale bars: 1,000 µm in A, D; 100 µm in B, E; 50 µm in C, F. Among the H. cinaedi patients, we were able to subculture isolates from 3; the range of blood culture growth times, 75.3–160.8 h (median 90.6 h), was longer than that among the non–H. cinaedi patients, 12.3–28.3 h (median 12.3 h). Drug susceptibility testing demonstrated levofloxacin-resistant H. cinaedi, although the sequence type on MLST was different in each case (Tables 1, 2).
Table 2

Bacteriological examination, method of treatment, and outcomes for 10 patients with infected aortic aneurysms with or without Helicobacter cinaedi, Aichi, Japan, September 2017–January 2021*

Patient no.Age, y/sexLocationBlood culturesIDComorbidityProcedure‡Antimicrobialuse periodOutcome
H. cinaedi group, n = 4†
172/MAortic arch75.3/negativeST6DMTAR (positive)6 moSurvival at 4 y
264/FRight common iliacNegativeUnknownDMY graft (negative)6 moSurvival at 3 y
383/MInfrarenal aorta86.5/160.8ST18Malignant lymphomaEVAR (NA)6 moSurvival at 2 y
4
88/M
Infrarenal aorta
90.6/93.0
ST21
CKD
Medical treatment only (NA)
3 mo
Survival at 1 y
Non–H. cinaedi group, n = 6§
170/MInfrarenal aortaNegativeMSSANoneY graft6 moSurvival at 4 y
274/MInfrarenal aortaNegative Listeria monocytogenes NoneY graft6 moSurvival at 4 y
367/MInfrarenal aorta12.6/12.6 Enterobacter cloacae AEFY graft6 moSurvival at 3 y
483/MInfrarenal aorta12.3/12.3MSSADMY graft3 moSurvival at 3 y
586/FThoracoabdominal aortaNegativeMSSANoneMedical treatment only3 moSurvival at 1 y
680/MInfrarenal aorta28.3/28.3 Salmonella enteritidis NoneY graftUntil deathDeath at POD 5

*DM, diabetes mellitus; CKD, chronic kidney disease; TAR, total arch replacement; EVAR, endovascular aortic repair; NA, not applicable; MSSA, methicillin-susceptible Staphylococcus aureus; AEF, aorto-enteric fistula; POD, postoperative day; ST, sequence type. †16S RNA results were positive for all patients. ‡Y graft replacement for abdominal aortic aneurysm. §Tissue culture results for all patients returned in 1 d; patient 5 had an abscess.

*DM, diabetes mellitus; CKD, chronic kidney disease; TAR, total arch replacement; EVAR, endovascular aortic repair; NA, not applicable; MSSA, methicillin-susceptible Staphylococcus aureus; AEF, aorto-enteric fistula; POD, postoperative day; ST, sequence type. †16S RNA results were positive for all patients. ‡Y graft replacement for abdominal aortic aneurysm. §Tissue culture results for all patients returned in 1 d; patient 5 had an abscess.

Conclusions

Infected aortic aneurysms caused by H. cinaedi are increasingly being recognized, especially in Japan, although the detection rate remains low (). One study reported 734 cases of infected aortic aneurysms caused by various organisms, including Salmonella, Staphylococcus, Streptococcus, and Escherichia coli, but not H. cinaedi (). Infected aortic aneurysms are a critical disease with high mortality, and whereas identifying the causative bacteria is effective in determining treatment, 23.3%–25% of cases are caused by unidentified bacteria (). In our study, the detection rate for H. cinaedi in infected aortic aneurysms was high, 40%, although the absolute number of cases was small. Of note, infections caused by H. cinaedi all showed good clinical courses. H. cinaedi is known to cause nosocomial infections; however, nosocomial infections were ruled out as mode of infection here because the 3 isolates that underwent MLST had different sequence types (). The Bactec FX system (https://www.bd.com), widely used for blood culturing of H. cinaedi, is generally considered to be more sensitive than the bioMérieux BacT/Alert system (). Nevertheless, by assuming H. cinaedi was the causative bacterium of the infected aortic aneurysms for our patients and simply allowing a longer incubation period of 10 days versus the usual 5 days, the BacT/Alert system detected the bacterium in 3/4 cases, comparable to the Bactec FX system (). It is sometimes difficult to grow bacterial subcultures in microaerophilic conditions; however, adding 5%–10% hydrogen effectively helps form characteristic thin-spread colonies (). PCR reliably detects and identifies species, but matrix-assisted laser desorption/ionization time-of-flight mass spectrometry is also useful (), although unfortunately this testing method results in a time lag between initiating treatment on and identifying bacteria. H. cinaedi infects atherosclerotic sites, leading to the progression of atherosclerosis through lipid accumulation (,). Progression is slow, often taking months, and leads to no clinical findings even if a local infection is established (,). Considering the slow, localized progression and difficulty of detection of atherosclerosis associated with H. cinaedi infection, aortic aneurysms thought to be noninfectious might actually be infected by H. cinaedi. Clarifying the relationship between this bacterium and atherosclerotic diseases might lead to additional treatments. No infected aortic aneurysms caused by H. cinaedi have resulted in rupture, and cases usually pass without recurrence following an appropriate period of antibiotic treatment. Because nonsurgical treatment has been shown to be effective, open surgery during the acute phase of infection might be overindicated. Endovascular stent grafting, a less invasive treatment than the standard vascular replacement procedure, followed by use of appropriate antimicrobial agents might successfully complete treatment (). This treatment is beneficial among aging patients, and it is hoped that the presence of these bacteria in infected aortic aneurysms will be widely recognized, with treatment and diagnosis proceeding simultaneously. In summary, although H. cinaedi is a relatively rare cause of infected aortic aneurysms, it might be overlooked because of its low initial detection rate. Detection during treatment initiation can improve patient life expectancy by enabling effective antimicrobial therapy and expanding treatment options.

Appendix

Additional information about determining treatment for infected aortic aneurysms through the focused detection of H. cinaedi.
  15 in total

1.  Molecular epidemiologic analysis and antimicrobial resistance of Helicobacter cinaedi isolated from seven hospitals in Japan.

Authors:  Emiko Rimbara; Shigetarou Mori; Mari Matsui; Satowa Suzuki; Jun-Ichi Wachino; Yoshiaki Kawamura; Zeli Shen; James G Fox; Keigo Shibayama
Journal:  J Clin Microbiol       Date:  2012-05-16       Impact factor: 5.948

2.  Helicobacter cinaedi and Helicobacter fennelliae transmission in a hospital from 2008 to 2012.

Authors:  Emiko Rimbara; Shigetarou Mori; Hyun Kim; Mari Matsui; Satowa Suzuki; Shunji Takahashi; Satoshi Yamamoto; Masaya Mukai; Keigo Shibayama
Journal:  J Clin Microbiol       Date:  2013-05-08       Impact factor: 5.948

Review 3.  Clinical and bacteriological characteristics of Helicobacter cinaedi infection.

Authors:  Yoshiaki Kawamura; Junko Tomida; Yuji Morita; Shigemoto Fujii; Tatsuya Okamoto; Takaaki Akaike
Journal:  J Infect Chemother       Date:  2014-07-09       Impact factor: 2.211

4.  A dramatic increase in the positive blood culture rates of Helicobacter cinaedi: the evidence of differential detection abilities between the Bactec and BacT/Alert systems.

Authors:  Noriko Miyake; Yong Chong; Ruriko Nishida; Yoji Nagasaki; Yasushi Kibe; Makiko Kiyosuke; Takeshi Shimomura; Nobuyuki Shimono; Shinji Shimoda; Koichi Akashi
Journal:  Diagn Microbiol Infect Dis       Date:  2015-07-26       Impact factor: 2.803

Review 5.  Systematic Review of the Management of Mycotic Aortic Aneurysms.

Authors:  Karl Sörelius; Jacob Budtz-Lilly; Kevin Mani; Anders Wanhainen
Journal:  Eur J Vasc Endovasc Surg       Date:  2019-07-16       Impact factor: 7.069

6.  In situ versus extra-anatomic reconstruction for primary infected infrarenal abdominal aortic aneurysms.

Authors:  Chun-Hui Lee; Hung-Chang Hsieh; Po-Jen Ko; Hao-Jui Li; Tsung-Chu Kao; Sheng-Yueh Yu
Journal:  J Vasc Surg       Date:  2011-02-12       Impact factor: 4.268

7.  Identification of and screening for human Helicobacter cinaedi infections and carriers via nested PCR.

Authors:  Kohta Oyama; Shahzada Khan; Tatsuya Okamoto; Shigemoto Fujii; Katsuhiko Ono; Tetsuro Matsunaga; Jun Yoshitake; Tomohiro Sawa; Junko Tomida; Yoshiaki Kawamura; Takaaki Akaike
Journal:  J Clin Microbiol       Date:  2012-09-26       Impact factor: 5.948

8.  First evidence of bacterial translocation from the intestinal tract as a route of Helicobacter cinaedi bacteremia.

Authors:  Hideki Araoka; Masaru Baba; Chikako Okada; Muneyoshi Kimura; Tomoaki Sato; Yutaka Yatomi; Kyoji Moriya; Akiko Yoneyama
Journal:  Helicobacter       Date:  2017-12-08       Impact factor: 5.753

9.  Clinical characteristics of bacteremia caused by Helicobacter cinaedi and time required for blood cultures to become positive.

Authors:  Hideki Araoka; Masaru Baba; Muneyoshi Kimura; Masahiro Abe; Hiroko Inagawa; Akiko Yoneyama
Journal:  J Clin Microbiol       Date:  2014-02-26       Impact factor: 5.948

10.  Cytolethal distending toxin: a potential virulence factor for Helicobacter cinaedi.

Authors:  Nancy S Taylor; Zhongming Ge; Zeli Shen; Floyd E Dewhirst; James G Fox
Journal:  J Infect Dis       Date:  2003-12-09       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.